Paragraf Expands into Magnetic and Molecular Sensing
Paragraf
The Cardea deal turns Paragraf from a single product sensor company into a graphene device company that can sell into two very different buying cycles with one manufacturing base. The same core graphene fabrication know how now feeds Hall sensors for cryogenic and high field magnetic measurement, and graphene field effect transistor chips for molecular detection, which lets Paragraf spread R&D, wafer process development, and factory utilization across both industrial and diagnostic markets.
-
On the magnetic side, Paragraf already sells graphene Hall sensors that operate from millikelvin temperatures up to 350K and measure fields up to 30 Tesla. That makes them useful inside quantum computing dilution refrigerators and other extreme environments where conventional silicon sensors need more amplification, shielding, or simply cannot operate as cleanly.
-
Cardea added the molecular side, including graphene biosensor IP and a biocompatible chip platform built for measuring changes in electrical conductivity when DNA, proteins, or other targets bind to the sensor surface. In practice, that moves Paragraf into cartridges and test workflows, not just instrumentation components.
-
The acquisition also added a U.S. footprint, which matters because diagnostics customers often want local manufacturing, regulatory support, and application development. That is already showing up in Paragraf's work with Tachmed, where the sensor is part of an at home diagnostic cartridge linked to cloud software rather than a standalone chip sale.
The next step is a broader product stack built on one graphene process, with magnetic sensors anchoring high performance industrial niches and molecular sensors opening larger volume healthcare and environmental markets. If Paragraf executes, the shared platform can compound faster than either business could on its own, because each new process improvement benefits both product lines.